Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- How will FDA regulate psychedelics?
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal









